Skip to main content
Clinical Trials/NCT05436730
NCT05436730
Active, not recruiting
Not Applicable

The Role of Ambulatory Blood Pressure Characteristics, Features of the Structural and Functional Vascular Wall State, the Presence and Severity of Obstructive Sleep Apnea Syndrome in Predicting the "Escape" Phenomenon of the Antihypertensive Therapy Efficacy.

Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADE1 site in 1 country165 target enrollmentSeptember 29, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Arterial Hypertension
Sponsor
Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADE
Enrollment
165
Locations
1
Primary Endpoint
Assessment of BP increasing higher the target level when taking the same therapy
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

A little attention is paid to the AHT efficacy escaping problem, which can be explained by the AHT correction simplicity and rapid achievement of the target BP level. Nevertheless, modern statistic data on the effective AH treatment described above let us assume that AHT correction is either totally absent or is untimely in case of the "escape" phenomenon development. This could be one of the main reasons for the high prevalence of ineffective AH treatment. The aim of this study is to determine AHT efficacy "escape" phenomenon timeline and its predictors in hypertensive patients.

Registry
clinicaltrials.gov
Start Date
September 29, 2015
End Date
December 30, 2025
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADE
Responsible Party
Principal Investigator
Principal Investigator

Mikhailova Oksana

Dr., clinical reseacher

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Eligibility Criteria

Inclusion Criteria

  • Arterial hypertension (AH) grade 1-3, stage I-II
  • High compliance during the follow-up period (≥ 85%)
  • Initially achieved target office BP levels while taking 2-3-component AHT

Exclusion Criteria

  • Secondary AH
  • Resistant AH,
  • AH III stage,
  • PAP- therapy,
  • type 2 diabetes mellitus,
  • pregnancy
  • history of low adherence to treatment

Outcomes

Primary Outcomes

Assessment of BP increasing higher the target level when taking the same therapy

Time Frame: 1-6 months

Assessment of attenuation of efficacy of previously adequate antihypertensive therapy by using different BP measurement methods

Secondary Outcomes

  • Disease course: assessment of major CVE and death occurrence(10 years)

Study Sites (1)

Loading locations...

Similar Trials